Merck & Company Inc (MRK)vsSerina Therapeutics Inc (SER)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
SER
Serina Therapeutics Inc
$1.88
+1.08%
HEALTHCARE · Cap: $26.40M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 50590671% more annual revenue ($65.77B vs $130,000). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
SER
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
-27.4%
Fair Value
$1.46
Current Price
$1.88
$0.42 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 154.9% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
ROE of -120.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : SER
The strongest argument for SER centers on Revenue Growth, Debt/Equity. Revenue growth of 154.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : SER
The primary concerns for SER are Market Cap, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while SER is a hypergrowth play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.20 — expect wider price swings.
SER is growing revenue faster at 154.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Serina Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology through its proprietary polymer-based drug delivery platform. This technology significantly enhances the efficacy of therapeutic agents, positioning Serina at the forefront of the biopharmaceutical industry. With a promising pipeline of product candidates and strategic partnerships, the company is well-equipped to drive sustainable growth and deliver impactful healthcare solutions, all while creating substantial value for its investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?